IL162602D0 - Pyrrolidine derivatives as prostaglandin modulators - Google Patents

Pyrrolidine derivatives as prostaglandin modulators

Info

Publication number
IL162602D0
IL162602D0 IL16260202A IL16260202A IL162602D0 IL 162602 D0 IL162602 D0 IL 162602D0 IL 16260202 A IL16260202 A IL 16260202A IL 16260202 A IL16260202 A IL 16260202A IL 162602 D0 IL162602 D0 IL 162602D0
Authority
IL
Israel
Prior art keywords
pyrrolidine derivatives
prostaglandin modulators
prostaglandin
modulators
pyrrolidine
Prior art date
Application number
IL16260202A
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US34262001P priority Critical
Application filed by Applied Research Systems filed Critical Applied Research Systems
Priority to PCT/EP2002/014593 priority patent/WO2003053923A2/en
Publication of IL162602D0 publication Critical patent/IL162602D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with heteroatoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
IL16260202A 2001-12-20 2002-12-19 Pyrrolidine derivatives as prostaglandin modulators IL162602D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US34262001P true 2001-12-20 2001-12-20
PCT/EP2002/014593 WO2003053923A2 (en) 2001-12-20 2002-12-19 Pyrrolidine derivatives as prostaglandin modulators

Publications (1)

Publication Number Publication Date
IL162602D0 true IL162602D0 (en) 2005-11-20

Family

ID=23342570

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16260202A IL162602D0 (en) 2001-12-20 2002-12-19 Pyrrolidine derivatives as prostaglandin modulators
IL16260204A IL162602A (en) 2001-12-20 2004-06-17 Pyrrolidine derivatives as prostaglandin modulators

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL16260204A IL162602A (en) 2001-12-20 2004-06-17 Pyrrolidine derivatives as prostaglandin modulators

Country Status (10)

Country Link
US (3) US7335680B2 (en)
EP (1) EP1458679B1 (en)
JP (1) JP4554931B2 (en)
AT (1) AT455758T (en)
AU (2) AU2002358772B2 (en)
CA (1) CA2469075C (en)
DE (1) DE60235198D1 (en)
ES (1) ES2337887T3 (en)
IL (2) IL162602D0 (en)
WO (1) WO2003053923A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4554931B2 (en) * 2001-12-20 2010-09-29 メルク セローノ ソシエテ アノニム Pyrrolidine derivatives as prostaglandin modulators
US7547715B2 (en) 2002-10-10 2009-06-16 Ono Pharmaceutical Co., Ltd. Endogenous repair factor production accelerator
KR100843244B1 (en) 2007-04-19 2008-07-02 삼성전자주식회사 Semiconductor device and method of fabricating the same
EP1841733A2 (en) 2004-11-08 2007-10-10 Allergan, Inc. Substituted pyrrolidone compounds as prostaglandin ep4 agonists
US7893107B2 (en) 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
US7557095B2 (en) * 2006-05-12 2009-07-07 Allergan, Inc. Therapeutic compounds
US7550448B2 (en) * 2006-05-24 2009-06-23 Allergan, Inc. Therapeutic compounds
US8507545B2 (en) 2007-05-08 2013-08-13 National University Corporation, Hamamatsu University School Of Medicine Cytotoxic T cell activator comprising EP4 agonist
EP2155733B1 (en) * 2007-05-23 2012-09-26 Allergan, Inc. Cyclic lactams for the treatment of glaucoma or elevated intraocular pressure
US7964596B2 (en) 2008-03-07 2011-06-21 Allergan, Inc. Therapeutic compounds
EP2149552A1 (en) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituted benzamide derivatives as modulators of EP2 receptors
EP2149554A1 (en) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolyamides as modulators for an EP2 receptor
EP2149551A1 (en) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(indol-3-ylalkyl)-(hetero)arylamid derivatives as modulators of EP2 receptors
WO2010052625A1 (en) * 2008-11-10 2010-05-14 Pfizer Limited Pyrrolidines
US20110287112A1 (en) 2009-01-30 2011-11-24 Ono Pharmaceutical Co., Ltd. Prostate cancer progression inhibitor and progression inhibition method
TW201326154A (en) 2011-11-28 2013-07-01 拜耳知識產權公司 Novel 2H-indazoles as EP2 receptor antagonists
EP2913047B1 (en) 2012-10-29 2019-05-08 Cardio Incorporated Pulmonary disease-specific therapeutic agent
WO2015056504A1 (en) 2013-10-15 2015-04-23 小野薬品工業株式会社 Drug-eluting stent graft

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2451160A1 (en) * 1973-10-30 1975-05-07 Du Pont 3-pyrazolidones and pyrazolidines
US3873566A (en) * 1973-02-28 1975-03-25 Du Pont 3-Pyrazolidinones and pyrazolidines
US3976660A (en) * 1974-08-15 1976-08-24 E. R. Squibb & Sons, Inc. Pyrrolidine derivatives
DE2527989A1 (en) * 1975-06-24 1977-01-27 Hoechst Ag Synthetic prostaglandin analogues - are specific and long acting luteolytics, secretion inhibitors, spasmolytics and antihypertensives
US4033989A (en) * 1975-09-17 1977-07-05 The Upjohn Company 9-Deoxy-PGF2 Analogs
US4003911A (en) * 1975-09-26 1977-01-18 E. I. Du Pont De Nemours And Company Selected 3-pyrrolidinones and 2,4-pyrrolidindiones
US4090019A (en) 1976-05-10 1978-05-16 Minnesota Mining And Manufacturing Company Geminal prostaglandin analogs
US4211876A (en) * 1979-06-13 1980-07-08 E. I. Du Pont De Nemours And Company 3-Pyrazolidinone carboxamides
US4753945A (en) 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US5091431A (en) 1988-02-08 1992-02-25 Schering Corporation Phosphodiesterase inhibitors
US5010086A (en) 1990-02-28 1991-04-23 Sterling Drug Inc. Imidazopyridines, compositions and use
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
US5605814A (en) 1993-08-31 1997-02-25 Merck Frosst Canada Inc. DNA encoding human prostaglandin receptor EP2
US6143746A (en) 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9514160D0 (en) 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
GB9417532D0 (en) 1994-08-31 1994-10-19 Zeneca Ltd Aromatic compounds
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
TW502026B (en) 1995-06-20 2002-09-11 Zeneca Ltd Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates
TW434240B (en) 1995-06-20 2001-05-16 Zeneca Ltd Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
US5834468A (en) 1995-07-07 1998-11-10 Zeneca Limited Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
KR20000010918A (en) 1996-05-10 2000-02-25 게리 엘. 윌콕스 Carboline derivative
US6043252A (en) 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
AU5320698A (en) 1996-11-20 1998-06-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituted dihydrobenzofurans as pde inhibitors
TR199901366T2 (en) 1996-12-20 1999-09-21 Pfizer Inc. Prevention / repair of bone mass loss with prostaglandin agonists.
AT404730B (en) * 1997-04-07 1999-02-25 Holderchem Ag Acrylic copolymers and polymer compositions, as well as building materials to their use as additives or admixtures to improve the properties of dispersions, and
DK1000035T3 (en) 1997-07-25 2003-03-17 Altana Pharma Ag Substituted 6-phenylphenanthridines
US6006735A (en) 1997-09-12 1999-12-28 Park Industries, Inc. Automated stoneworking system and method
US6156753A (en) 1997-10-28 2000-12-05 Vivus, Inc. Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6127363A (en) 1997-10-28 2000-10-03 Vivus, Inc. Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction
GB9725953D0 (en) 1997-12-08 1998-02-04 Pfizer Ltd Compounds useful in therapy
US6211197B1 (en) 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
GB9822238D0 (en) 1998-10-12 1998-12-09 Pfizer Ltd Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof
TR200201643T2 (en) 1999-12-22 2002-11-21 Pfizer Products Inc. The EP4 receptor selective agonists for the treatment of osteoporosis.
RU2288913C2 (en) * 2001-07-16 2006-12-10 Ф.Хоффманн-Ля Рош Аг Prostaglandin analogs, method for their preparing and pharmaceutical composition possessing selective agonistic activity with respect to ep4-receptor
JP4554931B2 (en) * 2001-12-20 2010-09-29 メルク セローノ ソシエテ アノニム Pyrrolidine derivatives as prostaglandin modulators

Also Published As

Publication number Publication date
US8058305B2 (en) 2011-11-15
US20080114051A1 (en) 2008-05-15
US7635713B2 (en) 2009-12-22
JP4554931B2 (en) 2010-09-29
ES2337887T3 (en) 2010-04-30
AU2002358772B2 (en) 2008-11-20
AT455758T (en) 2010-02-15
EP1458679B1 (en) 2010-01-20
AU2002358772A1 (en) 2003-07-09
CA2469075A1 (en) 2003-07-03
WO2003053923A2 (en) 2003-07-03
CA2469075C (en) 2011-09-13
DE60235198D1 (en) 2010-03-11
IL162602A (en) 2011-07-31
WO2003053923A3 (en) 2004-01-29
US20090292000A1 (en) 2009-11-26
US7335680B2 (en) 2008-02-26
EP1458679A2 (en) 2004-09-22
JP2005517665A (en) 2005-06-16
US20050176800A1 (en) 2005-08-11
AU2009200663B2 (en) 2011-09-15
AU2009200663A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
DE60236206D1 (en) Spiroazacyclic compounds as monoamin receptor modulators
EG22695A (en) Novel phenyl-propargylether derivatives
EG25614A (en) Novel pyrroles derivatives as pharmaceutical agents
DK1526134T3 (en) Triazolyltropane derivatives as CCR5 modulators
GB0117583D0 (en) Novel compounds
GB0110901D0 (en) Novel Compounds
AU2002360508A1 (en) Substituted hydroxyethylamines
AU2002246855A1 (en) Novel compounds
AU2002218266A1 (en) Novel indanylidene compounds
AU2002360083A1 (en) Mononuclearly filled microcapsules
JP2003144789A5 (en)
JP2002277803A5 (en)
AU2001274763A1 (en) Novel compounds
GB0119172D0 (en) Phenyl pyrrole derivatives
GB0108800D0 (en) Novel compounds
HK1086269A1 (en) 2-iminopyrrolidine derivatives
IL162105D0 (en) New indole derivatives as factor xainhibitors
AU2002246723A1 (en) Pyrimidineamines as angiogenesis modulators
AUPQ679400A0 (en) Microgel synthesis
ZA200309522B (en) Substituted cyclohexane-1-4diamine derivatives
GB0106247D0 (en) Improvements relating to supports
AU2003253535A1 (en) N-4-piperidinyl compounds as ccr5 modulators
GB0105895D0 (en) Novel compounds
HK1068608A1 (en) 3-Substituted-4-pyrimidone derivatives
AU2002359122A1 (en) Novel compounds